Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?

• Main Authors: Laura Jimbu (Author), Oana Mesaros (Author), Cristian Popescu (Author), Alexandra Neaga (Author), Iulia Berceanu (Author), Delia Dima (Author), Mihaela Gaman (Author), Mihnea Zdrenghea (Author)
• Format: Bog
• Udgivet: MDPI AG, 2021-03-01T00:00:00Z.
• Fag: article
• Online adgang: Connect to this object online.

Checkpoint inhibitors were a major breakthrough in the field of oncology. In September 2014, based on the KEYNOTE-001 study, the Food and Drug Administration (FDA) approved pembrolizumab, a programmed cell death protein 1 (PD-1) inhibitor, for advanced or unresectable melanoma. Up until now, seven P...